Targeting ANGPTL4 with MAR001: A Promising Approach for Reducing Elevated Triglycerides

Highlight

  • ANGPTL4 is a key regulator that inhibits lipoprotein lipase, impacting triglyceride metabolism.
  • MAR001, a monoclonal antibody against ANGPTL4, significantly lowers fasting triglyceride levels in adults with elevated triglycerides.
  • The phase 2b trial showed dose-dependent reductions in triglycerides up to 45% at 12 weeks, with a favorable safety profile.
  • This therapeutic approach may address residual cardiovascular risk associated with hypertriglyceridemia.

Study Background

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply